Skip to main content

Regentis Biomaterials Ltd.

corporate_fare Company Profile

Regentis Biomaterials Ltd.

RGNT·NYSE·Industrial Applications And Services·CIK 0001912966

Regentis Biomaterials Ltd. is a regenerative medicine company developing tissue repair solutions, with current efforts focused on orthopedic treatments using its Gelrin platform of degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone tissue. Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee to treat painful injuries to articular knee cartilage. According to the company, there is currently no approved off-the-shelf product in the United States for the cartilage repair market. GelrinC is approved as a device with a CE mark in Europe, and the company plans to look for strategic partners in Europe in connection therewith. The company holds 27 granted patents and 4 pending patent applications covering, in a large number of countries, compositions, delivery device, surgical and manufacturing features. In the Pilot Study, 56 patients were treated with GelrinC for articular cartilage injuries; improvements in KOOS and VAS pain measurement scores over two years were superior (100% greater improvement) to those seen with the traditional microfracture procedure, and patients continued to report further improvement and greater pain reduction of their knee and associated problems using GelrinC for four years.

Regentis Biomaterials Ltd. (NYSE:RGNT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 1 item for RGNT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Recent SEC coverage for RGNT spans 6-K.

Recent high-impact activity:

  • Regentis Signs Four-Year Exclusive Israeli Distribution Deal for GelrinC

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$13.65M
Diluted EPS
-$24.16
Op. Cash Flow
-$1.38M
Operating Income
-$6.97M
Total Debt
$1.2M
Debt / Equity
0.25×
Shares Outstanding
5.18M sh
Source: 20-F · filed 2026-02-27 · accession 0001213900-26-021722

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 6,660 shares in RGNT as of the October 30, 2026 settlement, a 46.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 46.6% of RGNT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,660 shares as of October 30, 2026
Change vs prior period▼ 46.0%
Days to cover1.00 at avg daily volume of 28,516
Daily short volume (FINRA facilities)46.6% of 55,573 shares on November 20, 2026
5-day average short volume39.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

RGNT files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$0.89 +5.99% today
52-week range · as of 2026-11-09 $0.89 – $15.5
Market cap
$5.05M
Volume
122.5K (2.4× avg)
3-mo avg 51.5K
Live data · 2026-11-22 12:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RGNT - Latest Insights

RGNT
Nov 09, 2026, 9:15 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.22
Real-time Price: $0.890 info
Change: -$0.330 (-27%) info
Market Cap: $5.047M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets